WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon® Pen (exenatide extended-release for injectable ...
SAN DIEGO and INDIANAPOLIS, Dec. 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that ...
Byetta (exenatide) is a prescription drug that’s used to treat type 2 diabetes. Byetta can cause side effects that range from mild to serious. Examples include nausea and vomiting. The active ...
ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced final results ...
The co and Eli Lilly (LLY) announces the FDA has approved more convenient patient storage instructions for BYETTA (exenatide) injection. BYETTA Pens can now be kept at a room temperature not to exceed ...
NEW YORK, Nov 15 (Reuters) - Novo Nordisk A/S said on Thursday it believes its experimental type 2 diabetes treatment will be as effective as the Eli Lilly and Co drug expected to be its main rival ...
US FDA APPROVES BYDUREON® PEN (EXENATIDE EXTENDED-RELEASE FOR INJECTABLE SUSPENSION) FOR ONCE-WEEKLY TREATMENT OF ADULTS with TYPE 2 DIABETES AstraZeneca today announced that the US Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback